Introduction
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma. Photochemotherapy with 8-methoxypsoralen followed by ultraviolet A (PUVA) is a well-established and effective treatment option for earlystage disease (1) . One of the action mechanisms of PUVA therapy is mediated by the induction of apoptosis of both keratinocytes and lymphocytes (2) .
Secondary localized cutaneous amyloidosis refers to clinically unapparent amyloid deposits within the skin. This is actually the most common type of localized cutaneous amyloidosis (3) . Amyloid deposits have been observed in inflammatory dermatoses and skin tumors (4) (5) (6) . There are also reports that investigated the apoptotic effect on basal keratinocytes following PUVA therapy, and the consequent enzymatically degradation of apoptotic keratinocytes to amyloid (7) .
To date, secondary cutaneous amyloidosis after PUVA phototherapy in patients with MF has not been reported.
Materials and methods
Between 2008 and 2011, the control biopsies of 61 patients with early-stage MF who were treated with PUVA and narrow band ultraviolet B (NBUVB) phototherapy were analyzed. The skin phototypes of all patients were classified according to the Fitzpatrick scale (types 1-6). The patients were staged by using the TNM system as stages 1a, 1b, 2a, 2b, 3, and 4. The clinical presentation of the disease was classified as classic (patch/plaque form), hypopigmented, poikilodermic, erythrodermic, folliculotropic, and pityriasis-lichenoides-chronica-like. Types of phototherapy were divided into PUVA and NUVB categories. Dosimetric parameters were recorded as number of sessions and cumulative doses.
To detect the accumulation of amyloid in papillary dermis, all biopsies were stained with crystal violet and Congo red, and accumulation of amyloid in relation to MF location was recorded as present or not.
Histologically, keratosis patterns were evaluated as normal, parakeratosis, and orthohyperkeratosis.
Epidermal changes were divided into normal, atrophic, and hyperplastic. Interface changes were classified as basal vacuolar changes and colloid bodies. Dermal inflammatory infiltration was evaluated as superficial perivascular, lichenoid, and without inflammation. In addition, dilated vessels, melanophages, extravasations of erythrocytes, and fibrosis were histologically evaluated. After phototherapy, secondary cutaneous amyloidosis was detected in 5 out of 61 patients with MF. All patients with secondary cutaneous amyloidosis were treated with PUVA. Their clinical data and treatment are summarized in Table 1 . The group included 2 male and 3 female patients, with a mean age of 53 years (range: 39 and 73). There were 4 patients with skin type 2, and 1 had skin type 1. There were 3 patients who had a classic variant of MF and 2 patients who had a poikilodermic variant of MF. None of the patients experienced a photoallergic reaction during PUVA phototherapy. Clinically, brownish macules and plaques of varying diameter with pruritus were seen in all patients ( Figure 1 ). These clinical findings were restricted to the MF lesions in all patients. The secondary amyloidosis appeared after a mean of 56 exposures (range: 30-81) and the mean cumulative PUVA radiation dose was 131.7 J/cm 2 (range: 31-305.5). The mean follow-up duration from the date of occurrence of the secondary amyloidosis was 18.2 weeks (range: 10-30). The clinical data and treatments are summarized in Table 1 . On histopathological evaluation, normal keratosis was seen in 2 cases, parakeratosis in 1 case, and orthohyperkeratosis in 2 cases. The epidermis was atrophic in 4 cases and hyperplastic in 1 case. In all 5 cases, basal vacuolar degeneration and colloid bodies were seen in the epidermis, and dilated vessels, melanophages, and fibrosis were detected in dermis (Figure 2 ). Extravasated erythrocytes were seen in 3 cases, perivascular lymphocyte infiltrations were seen in 4 cases, and lichenoid infiltration was seen only in 1 case. When stained with crystal violet and Congo red, an accumulation of amyloid in the papillary dermis was seen in all 5 patients (Figure 3) . The data are summarized in Table 2 
Results

Discussion
Amyloidosis can be subdivided into cutaneous amyloidosis and systemic amyloidosis with cutaneous involvement (8, 9) . Precipitations of amyloid were seen in the extracellular space of the dermis in both groups. In cutaneous amyloidosis, amyloid accumulates in the papillary dermis, whereas in systemic amyloidosis with cutaneous involvement, it accumulates in subpapillary layers, dermal appendages, and blood vessels (10, 11) . Secondary amyloid deposition may be found in association with skin tumors (basal cell carcinoma, actinic keratoses, squamous cell carcinoma, and skin appendage tumors) and benign lesions (e.g., seborrheic warts), solar elastosis, collagenoses (e.g., lupus erythematosus), and PUVA therapy (12) (13) (14) (15) (16) (17) .
PUVA therapy is a mainstay in the treatment of patients with psoriasis vulgaris, cutaneous T-cell lymphoma, and several other inflammatory skin diseases (18) . The mechanism of PUVA is phototoxic reactions that are the result of direct cellular damage caused by an inflammatory, nonimmunological mechanism (18).
PUVA primarily targets DNA (19) . Other important targets of psoralens are specific receptors, and in particular the epidermal growth factor receptor (20) . However, there are also effects on other cell membrane components (21) . More recently, it has been noticed that PUVA therapy can induce programmed cell death (apoptosis) in skininfiltrating T-helper lymphocytes and keratinocytes, and so it can cause interface changes (22) . There are 2 cell types found in the epidermis and dermis within the interface changes. These are melanophages and colloid bodies. Melanophages are dermal phagocytic cells of macrophage lineage that are able to engulf large amounts of melanin pigment released from epidermal basal layer keratinocytes and melanocytes that have been damaged by the interface change. Colloid bodies are thought to represent injured basal layer keratinocytes that have undergone amyloid degeneration (23, 24) .
Cytokeratin 5 is predominantly found in basal keratinocytes (25, 26) . In the pathogenesis of amyloidosis, a commonly accepted theory is that the apoptotic basal keratinocytes (colloid bodies) release cytokeratins, which are then covered with autoantibodies, phagocytized by macrophages, and enzymatically degraded to amyloid K (keratin-associated amyloid). It is a key feature of organlimited cutaneous amyloidosis (7, 25, 27) . Based on these results, antibodies against cytokeratin 5 may be used for diagnosing amyloidosis (7) .
We detected amyloidosis in skin biopsies taken from 5 patients with MF treated with PUVA. In all of the cases with amyloid deposits, we observed interface dermatitis characterized by basal vacuolar changes, colloid bodies, and melanophages. In our patients, changes accompanying the amyloid depositions were consistent with those, as mentioned in the literature, that are seen after PUVA treatment.
In our cases, exposure to PUVA and cumulative doses showed differences. Although this leads us to the conclusion that the development of amyloid depositions are not related to the dosage or to the duration of the treatment, we think that we should not make a definite comment on this since our cases are few in number.
The age of our patients with amyloid deposits ranged from 39 to 73. In their report about amyloid deposition after psoriasis therapy with PUVA, Grene and Cox found that the ages of their patients ranged from 35 to 80, which parallels the findings in our study (28) .
In addition to amyloid changes, in most of our cases, we observed epithelial atrophy, perivascular lymphocyte infiltration in the dermis, extravasated erythrocytes, fibrosis, and dilated vessels. In the literature, it was reported that hyperkeratosis, hypergranulosis, variable acanthosis, and epidermal atrophy could be seen in treatment with UV (29, 30) . Clinical presentation of the effects of amyloidosis varies. Organ-limited cutaneous amyloidosis often shows yellowish or brownish macules, papules, or plaques, whereas systemic amyloidosis often initially presents with petechiae, ecchymosis, and nonhealing ulcers. These differences are due to the localization of amyloid deposition. Organ-limited cutaneous amyloidosis occurs in the papillary dermis, whereas systemic amyloidosis affects the perivascular area in the deeper dermis. Perivascular amyloid deposition in systemic amyloidosis makes blood vessels fragile, causing intracutaneous microand macrohemorrhages (7) . In our patients, we detected brownish maculae as seen in organ-limited cutaneous amyloidosis.
On the basis of the results from our study, there was an association between PUVA treatment and secondary cutaneous amyloidosis. The association may occur frequently, but it may go unreported because the amyloid deposits may not be evident when stained with the usual stains, and also because the clinical findings are not apparent enough.
